CytomX Therapeutics (CTMX) News Today → Crypto Millionaire Says: “Buy This $11 AI Coin.” (From InvestorPlace) (Ad) Free CTMX Stock Alerts $1.94 +0.05 (+2.65%) (As of 04:30 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:43 AM | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) PT Raised to $3.59 at BMO Capital MarketsMay 13 at 4:44 AM | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for CytomX Therapeutics (NASDAQ:CTMX)May 13 at 3:12 AM | americanbankingnews.comAnalysts Set Expectations for CytomX Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CTMX)May 13 at 1:38 AM | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Upgraded to "Outperform" by WedbushMay 12 at 2:52 AM | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at StockNews.comMay 12 at 1:48 AM | americanbankingnews.comBrokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $6.42May 11 at 3:03 AM | wsj.comCytomX Therapeutics Inc.May 11 at 12:17 AM | marketbeat.comStockNews.com Upgrades CytomX Therapeutics (NASDAQ:CTMX) to BuyStockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.May 9, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comCautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug DataMay 9, 2024 | msn.comCytomX slides after early data for Amgen-partnered cancer drugMay 9, 2024 | markets.businessinsider.comAnalysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic CancerMay 9, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Hold" from AnalystsShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and two have assigned a buy ratinMay 9, 2024 | investorplace.comWhy Is CytomX (CTMX) Stock Down 43% Today?May 9, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) PT Raised to $3.59BMO Capital Markets raised their price objective on shares of CytomX Therapeutics from $3.25 to $3.59 and gave the stock a "market perform" rating in a research report on Thursday.May 9, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Thursday.May 9, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Lifted to Outperform at WedbushWedbush upgraded shares of CytomX Therapeutics from a "neutral" rating to an "outperform" rating and set a $8.00 target price for the company in a research note on Thursday.May 9, 2024 | finance.yahoo.comCytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | investorplace.comCTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comCytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)May 8, 2024 | globenewswire.comCytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comJefferies Financial Group Upgrades CytomX Therapeutics (NASDAQ:CTMX) to "Buy"May 7, 2024 | globenewswire.comCytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)May 7, 2024 | msn.comJefferies Upgrades CytomX Therapeutics (CTMX)May 6, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Raised to Buy at Jefferies Financial GroupJefferies Financial Group raised CytomX Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from $2.50 to $8.00 in a report on Monday.May 4, 2024 | americanbankingnews.comCytomX Therapeutics' (CTMX) Market Perform Rating Reiterated at BMO Capital MarketsMay 2, 2024 | marketbeat.comCytomX Therapeutics (CTMX) Scheduled to Post Earnings on WednesdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | marketbeat.comCytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 16,565 call options on the company. This is an increase of 7,197% compared to the average daily volume of 227 call options.May 1, 2024 | marketbeat.comBMO Capital Markets Reaffirms "Market Perform" Rating for CytomX Therapeutics (NASDAQ:CTMX)BMO Capital Markets restated a "market perform" rating and set a $3.25 target price on shares of CytomX Therapeutics in a report on Wednesday.May 1, 2024 | investorplace.comWhy Is CytomX (CTMX) Stock Up 180% Today?May 1, 2024 | marketbeat.comTrading was temporarily halted for "CTMX" at 10:05 AM with a stated reason of "LULD pause."May 1, 2024 | globenewswire.comCytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024May 1, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest UpdateCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,590,000 shares, a growth of 8.1% from the March 31st total of 3,320,000 shares. Based on an average trading volume of 905,200 shares, the short-interest ratio is currently 4.0 days.April 27, 2024 | seekingalpha.comCytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In TownApril 23, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by StockNews.comStockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday.April 23, 2024 | msn.comJP Morgan Upgrades CytomX Therapeutics (CTMX)April 22, 2024 | msn.comCytomX upgraded to Neutral at J.P MorganApril 22, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Neutral at JPMorgan Chase & Co.JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Monday.April 17, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (CTMX)April 8, 2024 | globenewswire.comCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsApril 3, 2024 | globenewswire.comCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasMarch 23, 2024 | investing.comCytomX Therapeutics executive sells over $26k in company stockMarch 23, 2024 | investing.comCytomX Therapeutics executive sells shares worth over $6,000March 22, 2024 | insidertrades.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Lloyd A. Rowland Sells 5,268 SharesMarch 21, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Sells 5,268 SharesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) General Counsel Lloyd A. Rowland sold 5,268 shares of the business's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $11,010.12. Following the transaction, the general counsel now owns 117,728 shares in the company, valued at $246,051.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.March 21, 2024 | globenewswire.comCytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsMarch 18, 2024 | globenewswire.comCytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasMarch 15, 2024 | marketbeat.comResearch Analysts Issue Forecasts for CytomX Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CTMX)CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities research analysts at Wedbush issued their FY2028 earnings estimates for shares of CytomX Therapeutics in a research note issued on Tuesday, March 12th. Wedbush analyst R. Driscoll forecasts that the biotechnology company will post eMarch 13, 2024 | finance.yahoo.comCytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 12, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN) and CytomX Therapeutics (CTMX) Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. CTMX Media Mentions By Week CTMX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.470.57▲Average Medical News Sentiment CTMX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼312▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Enanta Pharmaceuticals News Today Xeris Biopharma News Today Nektar Therapeutics News Today XBiotech News Today RAPT Therapeutics News Today Eliem Therapeutics News Today Inozyme Pharma News Today XOMA News Today Verastem News Today Design Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
